- Home
- AQB vs GLMD Comparison
AQB vs GLMD Comparison
Compare AQB & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- GLMD
- Stock Information
- Founded
- AQB 1991
- GLMD 2000
- Country
- AQB United States
- GLMD Israel
- Employees
- AQB N/A
- GLMD N/A
- Industry
- AQB
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- GLMD Health Care
- Exchange
- AQB Nasdaq
- GLMD Nasdaq
- Market Cap
- AQB 2.9M
- GLMD 3.0M
- IPO Year
- AQB N/A
- GLMD 2014
- Fundamental
- Price
- AQB $0.65
- GLMD $1.38
- Analyst Decision
- AQB Hold
- GLMD Hold
- Analyst Count
- AQB 1
- GLMD 1
- Target Price
- AQB N/A
- GLMD N/A
- AVG Volume (30 Days)
- AQB 3.0M
- GLMD 134.8K
- Earning Date
- AQB 05-14-2025
- GLMD 05-29-2025
- Dividend Yield
- AQB N/A
- GLMD N/A
- EPS Growth
- AQB N/A
- GLMD N/A
- EPS
- AQB N/A
- GLMD N/A
- Revenue
- AQB N/A
- GLMD N/A
- Revenue This Year
- AQB N/A
- GLMD N/A
- Revenue Next Year
- AQB N/A
- GLMD N/A
- P/E Ratio
- AQB N/A
- GLMD N/A
- Revenue Growth
- AQB N/A
- GLMD N/A
- 52 Week Low
- AQB $0.47
- GLMD $1.21
- 52 Week High
- AQB $2.17
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- AQB 48.06
- GLMD 39.62
- Support Level
- AQB $0.62
- GLMD $1.22
- Resistance Level
- AQB $0.69
- GLMD $1.54
- Average True Range (ATR)
- AQB 0.06
- GLMD 0.15
- MACD
- AQB -0.00
- GLMD 0.02
- Stochastic Oscillator
- AQB 36.94
- GLMD 47.22
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.